Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma.

Manegold, C; Symanowski, J; Gatzemeier, U; Reck, M; von Pawel, J; Kortsik, C; Nackaerts, K; Lianes, P; Vogelzang, N J

Manegold, C; Symanowski, J; Gatzemeier, U; Reck, M; von Pawel, J; Kortsik, C; Nackaerts, K; Lianes, P; Vogelzang, N J.

Affiliation

Manegold C; Heidelberg University Medical Center, Mannheim, Germany. Prof.Manegold@t-online.de

Ann Oncol ; 16(6): 923-7, 2005 Jun.

Article in En | MEDLINE | ID: mdl-15824080

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Cisplatin/therapeutic use; Glutamates/administration & dosage; Guanine/analogs & derivatives; Mesothelioma/drug therapy; Pleural Neoplasms/drug therapy; Adult; Aged; Aged, 80 and over; Cisplatin/administration & dosage; Female; Guanine/administration & dosage; Humans; Male; Mesothelioma/mortality; Middle Aged; Pemetrexed; Pleural Neoplasms/mortality; Retrospective Studies

Search on Google

XML

PubMed Links

Collection: 01-internacional Health context: 6_ODS3_enfermedades_notrasmisibles Database: MEDLINE Main subject: Pleural Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Cisplatin / Glutamates / Guanine / Mesothelioma Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Ann Oncol Year: 2005 Document type: Article

Search on Google

XML

PubMed Links